cGMP Custom Manufacturing of Tomorrow's Medicines
Cobra Biomanufacturing is dedicated to designing robust processes that deliver high-quality preclinical and clinical biopharmaceutical products for its international life-sciences customers. From proteins and viruses to DNA and cells, Cobra offers a full range of biomanufacturing services and has established an enviable track record in cGMP manufacturing.
Cobra Biomanufacturing is dedicated to designing robust processes that deliver high-quality preclinical and clinical biopharmaceutical products for its international life-sciences customers. From proteins and viruses to DNA and cells, Cobra offers a full range of biomanufacturing services and has established an enviable track record in cGMP manufacturing.
Exceeding Customer Expectations
Having originally worked for pharmaceutical and biotechnology companies ourselves we are sensitive to the unprecedented time and cost demands placed upon our customers in obtaining high-quality products for preclinical and clinical supply. Cobra's flexible and resourceful teams devise streamlined and optimized solutions to overcome the hurdles in making medicines. Besides developing conventional biopharmaceuticals, our scientists' skills and approaches enable us to excel in making difficult, complex, or emerging biopharmaceuticals.
Robust Manufacturing Processes
Cobra's state-of-the-art manufacturing facilities house eight flexible-scale, dedicated cGMP suites from which we supply materials for clinical trials to five continents: North America, Europe, South America, Australia, and Africa. We devise innovative technologies and solutions to improve manufacturing efficiency and safety, and we design robust processes for the guaranteed delivery of clinical products. For example, strains of bacteria have been engineered that produce lower levels of host contaminants, reducing costs and accelerating product purification. Consideration of future regulatory requirements and changes also served as a driver for Cobra's scientists to design vectors that can be maintained without antibiotics. Antibiotic-free selection reduces processing costs and provides a safer product. On another front, expression technologies have been and continue to be developed enabling rapid selection and isolation of mammalian cell lines expressing high levels of proteins.
Communication for Success
At Cobra, we recognize the value of transparent and effective communications with our customers. We ensure that we provide regular progress updates, as well as respond to our customers' needs. Large enough to deliver and small enough to care, Cobra dedicates the attention and resources needed with multidisciplinary teams that remain with each program throughout its life. This seamless integration reduces both transfer risk and time delays, thereby increasing customer satisfaction. Delivering the highest quality products on schedule through trusted relationships ensures that our customers come back for further clinical development and production—or with new projects.
Company info
Cobra Biomanufacturing
Stephenson Building,
Keele Science Park,
Keele ST5 5SP, UK
Tel: +44.178.287.7298
Email: philip.ridley-smith@cobrabio.com
Website: www.cobrabio.com
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Biophysical and Aggregate Characterization for the Development of Biologics
June 10th 2025This eBook explores how advanced particle analysis technologies are revolutionizing biologic drug development. It highlights the importance of accurately identifying and characterizing subvisible particles to ensure drug safety, stability, and regulatory compliance. Techniques like Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy (FMM) are often used for their capabilities in detecting protein aggregates and degraded excipients such as polysorbates. Case studies and experimental results demonstrate how these tools provide high-throughput, low-volume analysis that enhances decision-making in formulation screening and manufacturing.
Psilera, Hesperos Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
